ReviewDiscover oncology2026
Curcumin therapeutic potential in gastric cancer prevention, treatment and metastasis suppression.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a significant global health burden, characterized by high mortality rates, often due to late-stage diagnosis, resistance to conventional therapies, and metastatic dissemination. This narrative review synthesizes current preclinical and early clinical evidence on the diverse roles of curcumin, a natural polyphenolic compound derived from Curcuma longa (turmeric), in the context of gastric cancer. A comprehensive search of databases, including PubMed, Scopus, and Web of Science, was conducted, and approximately 140 studies were critically appraised to identify mechanistic insights and translational barriers. In this context, curcumin’s potential in preventing GC is explored, specifically regarding its potent anti-inflammatory and antioxidant properties, modulation of precancerous lesions, and anti-Helicobacter pylori activity. Furthermore, the review details curcumin’s mechanisms in treating established GC, including its ability to inhibit cancer cell proliferation, induce apoptosis (via pathways like PI3K/Akt/mTOR, NF-κB, STAT3), and exert anti-angiogenic effects. Crucially, its capacity to inhibit GC metastasis by reversing epithelial-mesenchymal transition (EMT), suppressing matrix metalloproteinases (MMPs), and modulating key signaling pathways involved in invasion and migration is highlighted. Additionally, curcumin’s role in overcoming chemoresistance is discussed. Despite its promising pleiotropic actions, the clinical translation of curcumin is significantly challenged by its poor bioavailability. Moreover, various strategies to enhance systemic absorption are addressed, emphasizing the critical need for well-designed clinical trials to validate its efficacy and safety in human GC patients. This review underscores curcumin’s potential as a valuable complementary or integrative therapeutic agent in gastric cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.